Enzymatica ABThe CEO of Lund-based Enzymatica AB, Claus Egstrand, is stepping down from his role. CFO Therese Filmersson will also leave her position. The process of finding their successors has already begun.
MC2 Therapeutics A/SMC2 Therapeutics A/S, a Hørsholm-based pharmaceutical company focused on topical therapies in inflammatory skin conditions, announced the appointment of Trine Ahlgreen as Chief Executive Officer at the end of May.
Sibylla BiotechItalian Sibylla Biotech has appointed a new Chairman of the Board of Directors: Dieter Weinand, former President, CEO and Chairman of the Board of Bayer Pharmaceuticals AG.
Angeline VenturesDr Regina Hodits joined Angelini Ventures, the VC arm of Angelini Industries, in April as the new Managing Director. She will be based in Germany and lead the company’s international biotech investment strategy with focus Biotech AI and therapeutics.
4basebioCambridge-based 4basebio PLC announced the appointment of Gabe Longoria as Chief Commercial Officer.
OSE TherapeuticsDr Sonya Montgomery joined OSE Immunotherapeutics SA, based in Nantes, France, as Chief Development Officer.
Nucleara LtdCambridge-based biotechnology company Nuclera has appointed William J. Kullback to its board of directors as a non-executive director.
Single Use SupportKufstein-based Single Use Support appointed Darren Verlenden as CEO and strengthens leadership team.
BiosynthMatt Gunnison was appointed as the new CEO of Biosynth, headquartered in Staad (CH). He started in November.
DiogenX SAThe French biotech company DiogenX is further strengthening its management team. In November, Dr Klara Owen was appointed as Chief Medical Officer.